2024
Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
Ayoade O, Canavan M, Caturegli G, Boffa D. Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation? Lung Cancer 2024, 198: 108032. PMID: 39561624, DOI: 10.1016/j.lungcan.2024.108032.Peer-Reviewed Original ResearchNon-small cell lung cancerAssociated with superior survivalSuperior survivalStage III NSCLC patientsCancer historyIII NSCLC patientsReceipt of immunotherapyNational Cancer DatabaseRegimens of chemotherapyStage IV patientsAnalyze overall survivalCell lung cancerKaplan Meier analysisStage III andCox proportional hazards modelsProportional hazards modelInnovative treatment approachesInfluence patient outcomesNSCLC patientsIV patientsOverall survivalImmunotherapy trialsCancer DatabaseMeier analysisNon-small
2023
Assessment of a collaborative treatment model for trimodal management of esophageal cancer
Udelsman B, Ermer T, Ely S, Canavan M, Zhan P, Boffa D, Blasberg J. Assessment of a collaborative treatment model for trimodal management of esophageal cancer. Journal Of Thoracic Disease 2023, 15: 4668-4680. PMID: 37868899, PMCID: PMC10586936, DOI: 10.21037/jtd-23-346.Peer-Reviewed Original ResearchPathologic complete responseNational Cancer DatabaseGy of radiationEsophageal cancerCollaborative treatmentCollaborative treatment modelMultiagent chemotherapySingle institutionRate of pCRPatient travel burdenR0 resection rateTreatment modelTrimodality therapyTrimodality treatmentNeoadjuvant chemoradiotherapyNeoadjuvant therapyR0 resectionResection rateComplete responseMultivariable analysisTumor characteristicsCancer DatabaseMedian travel distancePatientsCollaborative CohortOverall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortality
2022
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studiesNonregional Lymph Nodes as the Only Metastatic Site in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Boffa D. Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100426. PMID: 36444359, PMCID: PMC9700291, DOI: 10.1016/j.jtocrr.2022.100426.Peer-Reviewed Original ResearchStage IV esophageal cancerNonregional lymph nodesEsophageal cancerSystemic metastasesLymph nodesMultiorgan metastasesOrgan metastasisSuperior survivalAcademic facility typesOnly metastatic siteNational Cancer DatabaseOutcomes of patientsPatients 18 yearsRetrospective cohort studyStage IV diseaseKaplan-Meier analysisSquamous cell carcinomaPropensity-matched sampleNonregional lymphCohort studyMetastatic involvementMetastatic sitesCell carcinomaCancer DatabaseCox model